Preemptive interventions against errors need to become a priority for neuropsychiatric translational medicine. Our review of error sources provides little evidence that investigators can detect, manage, or correct effects from error intrusions once embarked on drug developments or data analyses (25). Early lapses in concentration during planning leave designs and methods vulnerable to inevitable human mistakes and the errors that result from these mistakes. Successes against undetected errors in CTs will depend on the introduction of preventive methods found effective in other areas of scientific practice (12, 25). Drug development researchers should work to develop community-wide standards for prevention of errors in CTs and avoidance of undetected CT invalidation.
